##  [Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression](/us-en/news/media-releases/novartis-gains-fda-approval-gilenyatm-novel-first-line-multiple-sclerosis-treatment-shown-significantly-reduce-relapses-and-delay-disability-progression-0 "Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression") 

  Sep 22, 2010